80.68
price down icon2.16%   -1.78
after-market Handel nachbörslich: 80.68
loading
Schlusskurs vom Vortag:
$82.46
Offen:
$82.5
24-Stunden-Volumen:
330.28K
Relative Volume:
0.62
Marktkapitalisierung:
$5.36B
Einnahmen:
-
Nettoeinkommen (Verlust:
$-224.29M
KGV:
-20.69
EPS:
-3.9
Netto-Cashflow:
$-185.06M
1W Leistung:
-2.74%
1M Leistung:
+7.57%
6M Leistung:
-0.79%
1J Leistung:
-0.57%
1-Tages-Spanne:
Value
$80.39
$83.00
1-Wochen-Bereich:
Value
$80.39
$86.83
52-Wochen-Spanne:
Value
$55.53
$113.51

Nuvalent Inc Stock (NUVL) Company Profile

Name
Firmenname
Nuvalent Inc
Name
Telefon
508-446-2272
Name
Adresse
ONE BROADWAY, 14TH FLOOR, CAMBRIDGE
Name
Mitarbeiter
162
Name
Twitter
Name
Nächster Verdiensttermin
Name
Neueste SEC-Einreichungen
Name
NUVL's Discussions on Twitter

Vergleichen Sie NUVL mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
NUVL
Nuvalent Inc
80.68 5.96B 0 -224.29M -185.06M -3.90
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
470.13 119.21B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
560.93 59.16B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
325.28 40.57B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
571.23 34.02B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
295.59 29.19B 3.81B -644.79M -669.77M -6.24

Nuvalent Inc Stock (NUVL) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-03-14 Hochstufung UBS Neutral → Buy
2024-12-30 Eingeleitet H.C. Wainwright Buy
2024-10-24 Eingeleitet UBS Neutral
2024-08-29 Eingeleitet Barclays Overweight
2024-04-17 Eingeleitet Jefferies Buy
2024-04-01 Hochstufung Leerink Partners Market Perform → Outperform
2024-02-28 Fortgesetzt Guggenheim Buy
2024-02-23 Eingeleitet Robert W. Baird Outperform
2023-09-27 Eingeleitet Stifel Buy
2023-08-08 Eingeleitet SVB Securities Market Perform
2023-07-24 Eingeleitet Guggenheim Buy
2023-01-18 Eingeleitet Wedbush Outperform
2022-06-24 Eingeleitet BMO Capital Markets Outperform
Alle ansehen

Nuvalent Inc Aktie (NUVL) Neueste Nachrichten

pulisher
Jul 22, 2025

What drives Nuvalent Inc. stock priceGame-changing returns - Autocar Professional

Jul 22, 2025
pulisher
Jul 22, 2025

Is Nuvalent Inc. a good long term investmentHigh-impact stock picks - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

Nuvalent Inc. Stock Analysis and ForecastRapidly expanding wealth - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 22, 2025

What analysts say about Nuvalent Inc. stockUnprecedented profit potential - jammulinksnews.com

Jul 22, 2025
pulisher
Jul 21, 2025

Nuvalent Initiates Phase 3 ALKAZAR Trial of Neladalkib in NSCLC - Pharmacy Times

Jul 21, 2025
pulisher
Jul 21, 2025

Nuvalent begins Phase 3 trial of neladalkib in ALK-positive lung cancer - Investing.com

Jul 21, 2025
pulisher
Jul 21, 2025

Nuvalent Initiates Phase 3 ALKAZAR Clinical Trial - TipRanks

Jul 21, 2025
pulisher
Jul 21, 2025

Nuvalent doses first patient in phase 3 lung cancer drug trial - Investing.com India

Jul 21, 2025
pulisher
Jul 21, 2025

Nuvalent announces initiation of Alkazar phase 3 randomized - MarketScreener

Jul 21, 2025
pulisher
Jul 21, 2025

Nuvalent Announces Initiation of ALKAZAR Phase 3 Randomized, Controlled Trial Evaluating Neladalkib for Patients with TKI-naïve ALK-positive NSCLC - PR Newswire

Jul 21, 2025
pulisher
Jul 18, 2025

How high can Nuvalent Inc. stock price go in 2025Profitable Yet Secure Picks - Newser

Jul 18, 2025
pulisher
Jul 16, 2025

Nuvalent(NUVL) Shares Soar 3.01% on Positive Clinical Data - AInvest

Jul 16, 2025
pulisher
Jul 16, 2025

Nuvalent, Inc. (NASDAQ:NUVL) Stock Position Decreased by Teacher Retirement System of Texas - Defense World

Jul 16, 2025
pulisher
Jul 15, 2025

Why Nuvalent Inc. stock attracts strong analyst attentionDaily Trade Opportunity - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

How Nuvalent Inc. stock performs during market volatilityFree Capital Allocation Plans - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

What makes Nuvalent Inc. stock price move sharplyFree Access to Stock Community - Newser

Jul 15, 2025
pulisher
Jul 15, 2025

Recent Analysts’ Ratings Updates for Nuvalent (NUVL) - Defense World

Jul 15, 2025
pulisher
Jul 14, 2025

Insider Selling: Nuvalent, Inc. (NASDAQ:NUVL) Insider Sells $439,890.00 in Stock - Defense World

Jul 14, 2025
pulisher
Jul 11, 2025

Nuvalent's Insider Sales and Clinical Milestones: A Balancing Act for Investors - AInvest

Jul 11, 2025
pulisher
Jul 09, 2025

Nuvalent(NUVL) Shares Soar 3.47% on Positive Lung Cancer Data - AInvest

Jul 09, 2025
pulisher
Jul 07, 2025

Nuvalent Announces Positive Pivotal Data for Zidesamtinib in Lung Cancer - MSN

Jul 07, 2025
pulisher
Jul 07, 2025

Nuvalent’s SWOT analysis: biotech stock’s pivotal year ahead By Investing.com - Investing.com Nigeria

Jul 07, 2025
pulisher
Jul 07, 2025

Nuvalent’s SWOT analysis: biotech stock’s pivotal year ahead - Investing.com

Jul 07, 2025
pulisher
Jul 06, 2025

10 Best High Short Interest Stocks With Huge Upside Potential - Insider Monkey

Jul 06, 2025
pulisher
Jul 05, 2025

Nuvalent (NUVL) Gets a Buy from Goldman Sachs - The Globe and Mail

Jul 05, 2025
pulisher
Jul 03, 2025

Nuvalent (NASDAQ:NUVL) Upgraded at The Goldman Sachs Group - Defense World

Jul 03, 2025
pulisher
Jul 01, 2025

Goldman Sachs initiates coverage on Nuvalent stock with Buy rating By Investing.com - Investing.com India

Jul 01, 2025
pulisher
Jun 30, 2025

Goldman Sachs initiates coverage on Nuvalent stock with Buy rating - Investing.com

Jun 30, 2025
pulisher
Jun 27, 2025

Nuvalent chief development officer Noci sells $314k in shares - Investing.com

Jun 27, 2025
pulisher
Jun 26, 2025

Barclays Sticks to Its Buy Rating for Nuvalent (NUVL) - The Globe and Mail

Jun 26, 2025
pulisher
Jun 25, 2025

Nuvalent Believes Safety Profile Can Help Zidesamtinib Be ROS-1 Lung Cancer Leader - insights.citeline.com

Jun 25, 2025
pulisher
Jun 25, 2025

Nuvalent (NUVL) Receives Raised Price Target from Baird | NUVL Stock News - GuruFocus

Jun 25, 2025

Finanzdaten der Nuvalent Inc-Aktie (NUVL)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$21.80
price up icon 0.51%
$36.10
price up icon 1.26%
$102.92
price up icon 0.14%
$26.54
price up icon 0.76%
$111.44
price up icon 2.32%
biotechnology ONC
$295.59
price up icon 1.25%
Kapitalisierung:     |  Volumen (24h):